Compounded GLP-1s For Obesity: Is The Genie Out Of The Bottle?

Patient demand for compounded versions of FDA-approved obesity drugs is unlikely to dissipate, even if semaglutide’s “shortage” status is resolved. The issue likely will continue to be a high-profile concern for the brand industry.